1. PRLog Home
  2. Business Index
  3. Pressroom Index
  4. Press Releases Home
  1. About
  2. Press Room
  3. Contact
Filter By Industry
Filter By Tag

Press Room

NAPSRx Press releases

1 - 10 of 272 Press Releases

Oct 30, 2014
The Bayer Group has released their third quarter earnings for the 2014 financial year and the company beat analysts’ expectations posting a 13% rise in third-quarter net profit.

Oct 29, 2014
Bristol-Myers Squibb (BMS) has announced their plans to enter into an agreement with F-star Alpha Ltd. giving them the option to obtain the worldwide rights to FS102, a novel Phase 1 ready Human Epidermal growth factor Receptor 2 (HER2)-targeted therapy.

Oct 28, 2014
In a strategic move to strengthen their vaccine division, Australia’s CSL Ltd will pay Novartis $275 million for their global influenza vaccine business.

Oct 27, 2014
“The approval of this product provides an important therapeutic option for use in the care of patients with this rare disease,” said Karen Midthun, MD, director of FDA’s Center for Biologics Evaluation and Research.

Oct 24, 2014
Celgene Corporation had a remarkable financial third quarter earning a net income of $508 million for 2014 compared to $372 million in 2013.

Oct 22, 2014
Johnson & Johnson (NYSE: JNJ) will spend $200 million for further expansion on their Ebola vaccine program at Janssen Pharmaceuticals.

Oct 21, 2014
The Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) to the US Food and Drug Administration (FDA) made a unanimous decision to support the approval of Novartis’ investigational selective interleukin-17A (IL-17A) inhibitor, AIN457...

Oct 20, 2014
There are many reasons why pharmaceutical sales positions are desired by many aspiring job seekers in the healthcare industry.

Oct 17, 2014
Roche revealed an impressive financial report for their third quarter with notable sales growth in the pharmaceuticals division.  Group sales were 11.78 billion Swiss francs ( $12.5 billion) up 5% compared to last year.

Oct 16, 2014
The U.S. Food and Drug Administration has approved two new therapies for the treatment of idiopathic pulmonary fibrosis (IPF) these are Roche’s Esbriet (pirfenidone) and Boehringer Ingelheim’s  OFEV™ (nintedanib*).



RSS Feed for NAPSRx Press Releases